日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer

INHBA(+)癌相关成纤维细胞在卵巢癌中产生免疫抑制性肿瘤微环境

Ye Hu ,Maria Sol Recouvreux ,Marcela Haro ,Enes Taylan ,Barbie Taylor-Harding ,Ann E Walts ,Beth Y Karlan ,Sandra Orsulic

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

同源重组缺陷的肿瘤依赖于氧化代谢:与 PARP 抑制剂治疗的相关性

Álvaro Lahiguera, Petra Hyroššová, Agnès Figueras, Diana Garzón, Roger Moreno, Vanessa Soto-Cerrato, Iain McNeish, Violeta Serra, Conxi Lazaro, Pilar Barretina, Joan Brunet, Javier Menéndez, Xavier Matias-Guiu, August Vidal, Alberto Villanueva, Barbie Taylor-Harding, Hisashi Tanaka, Sandra Orsulic, 

Screening cell mechanotype by parallel microfiltration

通过平行微滤筛选细胞机械类型

Dongping Qi, Navjot Kaur Gill, Chintda Santiskulvong, Joshua Sifuentes, Oliver Dorigo, Jianyu Rao, Barbie Taylor-Harding, W Ruprecht Wiedemeyer, Amy C Rowat

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

细胞周期蛋白 E1 和 RTK/RAS 信号通过激活 E2F 和 ETS 驱动 CDK 抑制剂耐药性

Barbie Taylor-Harding, Paul-Joseph Aspuria, Hasmik Agadjanian, Dong-Joo Cheon, Takako Mizuno, Danielle Greenberg, Jenieke R Allen, Lindsay Spurka, Vincent Funari, Elizabeth Spiteri, Qiang Wang, Sandra Orsulic, Christine Walsh, Beth Y Karlan, W Ruprecht Wiedemeyer

VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2

VEGFR3 抑制通过下调 BRCA1 和 BRCA2 增强卵巢癌干细胞化学敏感性

Jaeyoung J Lim, Kun Yang, Barbie Taylor-Harding, W Ruprecht Wiedemeyer, Ronald J Buckanovich